Premium
Selenium–Platinum Coordination Compounds as Novel Anticancer Drugs: Selectively Killing Cancer Cells via a Reactive Oxygen Species (ROS)‐Mediated Apoptosis Route
Author(s) -
Zeng Lingwu,
Li Yang,
Li Tianyu,
Cao Wei,
Yi Yu,
Geng Weijia,
Sun Zhiwei,
Xu Huaping
Publication year - 2014
Publication title -
chemistry – an asian journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.18
H-Index - 106
eISSN - 1861-471X
pISSN - 1861-4728
DOI - 10.1002/asia.201402256
Subject(s) - reactive oxygen species , selenium , chemistry , apoptosis , cisplatin , cytotoxicity , platinum , in vivo , cancer cell , x ray photoelectron spectroscopy , biochemistry , in vitro , cancer , organic chemistry , biology , microbiology and biotechnology , chemotherapy , genetics , catalysis , physics , nuclear magnetic resonance
We report the preparation of selenium‐containing platinum‐based anticancer drug EG‐Se/Pt. EG‐Se/Pt was obtained from the coordination of selenium‐containing molecules (EG‐Se) with cisplatin (CDDP). The structure of EG‐Se/Pt was characterized by 1 H and 77 Se NMR spectroscopy, XPS, ESI‐MS, and MALDI‐TOF. In aqueous solution, EG‐Se/Pt self‐assembles to form spherical aggregates. EG‐Se/Pt shows enhanced stability against dilution and high salt concentration compared with EG‐Se. EG‐Se/Pt induces cell apoptosis via reactive oxygen species (ROS), which leads to high selectivity between cancer cells and normal cells in cytotoxicity assays. More importantly, EG‐Se/Pt effectively inhibits tumor growth in vivo in tumor‐bearing mice. It is anticipated that tuning the ROS level through the assembly of selenium‐containing molecules can be a general method to realize anticancer selectivity.